An anti-inflammatory drug normally used for rheumatoid arthritis could turn out to be a lifesaver for people hospitalized with COVID-19, a large clinical trial indicates. U.K. researchers announced Thursday that the immune suppressant baricitinib reduced the risk of dying among hospitalized COVID-19 patients by 13%. The remedy seemed especially effective when combined with other drugs, such as the readily available steroid dexamethasone, that also act on the immune system and have proven helpful in the fight against the novel coronavirus, researchers said. “Adding baricitinib on top of whateve…